 HYDERABAD, India--BUSINESS WIRE--Dr. Reddys Laboratories Ltd BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY announced today that it has received approval from the Drugs Control General of India DCGI to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and Safety Monitoring Board DSMB revi 